Spagnolo, F.; Dalmasso, B.; Tanda, E.; Potrony, M.; Puig, S.; van Doorn, R.; Kapiteijn, E.; Queirolo, P.; Helgadottir, H.; Ghiorzo, P.
Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. Cancers 2021, 13, 2440.
https://doi.org/10.3390/cancers13102440
AMA Style
Spagnolo F, Dalmasso B, Tanda E, Potrony M, Puig S, van Doorn R, Kapiteijn E, Queirolo P, Helgadottir H, Ghiorzo P.
Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. Cancers. 2021; 13(10):2440.
https://doi.org/10.3390/cancers13102440
Chicago/Turabian Style
Spagnolo, Francesco, Bruna Dalmasso, Enrica Tanda, Miriam Potrony, Susana Puig, Remco van Doorn, Ellen Kapiteijn, Paola Queirolo, Hildur Helgadottir, and Paola Ghiorzo.
2021. "Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants" Cancers 13, no. 10: 2440.
https://doi.org/10.3390/cancers13102440
APA Style
Spagnolo, F., Dalmasso, B., Tanda, E., Potrony, M., Puig, S., van Doorn, R., Kapiteijn, E., Queirolo, P., Helgadottir, H., & Ghiorzo, P.
(2021). Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. Cancers, 13(10), 2440.
https://doi.org/10.3390/cancers13102440